Insulin Aspart Sanofi (Insulin Aspart)

Insulin Aspart mimics natural human insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular signaling that moves glucose‑transport proteins to the cell surface, allowing glucose to enter cells and lower circulating blood‑sugar levels. Its modified structure enables a faster onset of action after injection.

The dose of Insulin Aspart is individualized. A qualified prescriber determines the total daily dose, the timing relative to meals, and any dose adjustments based on self‑monitoring of blood glucose, carbohydrate intake, and patient‑specific factors. No fixed dosing regimen is provided in public information.

Insulin Aspart may be used during pregnancy and lactation only when the expected benefit to the mother outweighs potential risks to the fetus or infant. It is classified as a pregnancy‑category drug where data are limited; clinicians should evaluate each case and monitor glucose closely.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Insulin Aspart Sanofi. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Insulin Aspart shares a rapid onset and short duration with other rapid‑acting analogues such as insulin lispro and insulin glulisine. Its amino‑acid substitution results in slightly faster hexamer dissociation, which may provide marginally earlier post‑prandial glucose control. Clinical efficacy and safety are comparable, and choice often depends on physician preference, patient response, and formulary considerations.

Unopened vials or cartridges of Insulin Aspart should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen. Once in use, the product may be kept at controlled room temperature (up to 25 °C) for up to 28 days, but should remain in its original container to protect from moisture and light.

Insulin Aspart is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. It is usually injected immediately before a meal (within 5–10 minutes) to cover the rise in blood glucose that follows eating. Patients should rotate injection sites to reduce the risk of lipodystrophy.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local swelling to anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical help if a severe allergic response occurs.

Insulin Aspart should be avoided in individuals with a known hypersensitivity to insulin aspart or any of its excipients. It is also contraindicated in patients experiencing hypoglycemia at the time of dosing. Clinicians should assess renal or hepatic impairment, as dose adjustments may be required.